Jefferies Keeps Their Buy Rating on Ultragenyx Pharmaceutical …

Oct. 7, 2024, 06:06 AM. In a report released today, Maury Raycroft from Jefferies maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of …

CouponFollow Extension

$70.00
OFF

Evercore ISI Keeps Their Buy Rating On Ultragenyx Pharmaceutical …

1 week from now

5 days ago · In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $70.00.The …

businessinsider.com

$67.00
OFF

Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating …

1 week from now

5 days ago · The Goldman Sachs Group increased their target price on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a research note on …

marketbeat.com

$80
OFF

Ultragenyx Pharmaceutical Inc. - MarketWatch

1 week from now

Ultragenyx stock price target raised to $80 from $75 at SunTrust RH. Jan. 10, 2020 at 7:29 a.m. ET by Tomi Kilgore.

marketwatch.com

$130.00
OFF

Analysts Are Bullish On These Healthcare Stocks: Ultragenyx ...

1 week from now

Jan 8, 2024 · In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $130.00. The company’s …

businessinsider.com

$129.00
OFF

Analysts Offer Insights On Healthcare Companies ... - Markets Insider

1 week from now

Apr 10, 2024 · Jefferies analyst Maury Raycroft maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $129.00. The company’s shares closed last …

businessinsider.com

$81.00
OFF

Barclays Sticks To Its Buy Rating For Ultragenyx Pharmaceutical …

1 week from now

Oct. 1, 2024, 01:46 AM. In a report released today, Gena Wang from Barclays maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $81.00. …

businessinsider.com

$72.00
OFF

Analysts Have Conflicting Sentiments On These Healthcare …

1 week from now

Jun 12, 2024 · In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $72.00. The company’s shares …

businessinsider.com

$383.00
OFF

TD Cowen Keeps Their Buy Rating On Amgen (AMGN)

1 week from now

4 days ago · In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $383.00. The company’s shares …

businessinsider.com

FAQs about Jefferies Keeps Their Buy Rating on Ultragenyx Pharmaceutical … Coupon?

Should you buy Ultragenyx Pharmaceutical (rare – research report)?

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $70.00. The company’s shares closed yesterday at $50.73. According to TipRanks, Bayko is a 5-star analyst with an average return of 11.4% and a 49.48% success rate. ...

Should you buy Raycroft & Ultragenyx Pharmaceutical?

According to TipRanks, Raycroft has an average return of 7.4% and a 40.08% success rate on recommended stocks. Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $87.56, which is a 62.78% upside from current levels. ...

How did Ultragenyx Pharmaceutical perform compared to last year?

Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $147.03 million and a GAAP net loss of $131.6 million. In comparison, last year the company earned a revenue of $108.31 million and had a GAAP net loss of $159.83 million ...

What is Ultragenyx & Crysvita?

Begin your TipRanks Premium journey today. Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. ...

Is Ultragenyx a good choice for evkeeza® (Evinacumab)?

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research ... ...

Is Raycroft a good stock to buy?

The company’s shares closed last Friday at $53.79. Raycroft covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ultragenyx Pharmaceutical, and KalVista Pharmaceuticals. According to TipRanks, Raycroft has an average return of 7.4% and a 40.08% success rate on recommended stocks. ...